Related Experiment Video
Updated: Oct 15, 2025
07:32
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
11.5K
Oligo(Lactic Acid)8-Docetaxel Prodrug-Loaded PEG-b-PLA Micelles for Prostate Cancer.
Lauren Repp1, Christopher J Unterberger1, Zhengqing Ye2
1Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
Nanomaterials (Basel, Switzerland)
|October 23, 2021
Summary
A novel docetaxel (DTX) prodrug, oligo(lactic acid)8-docetaxel, was formulated into stable polymeric micelles. These micelles demonstrated efficacy comparable to Taxotere® but with reduced toxicity in preclinical prostate cancer models.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Nanotechnology
Background:
- Docetaxel (DTX) is a vital chemotherapy for advanced prostate cancer, but its poor water solubility and toxic formulation limit clinical use.
- Existing polymeric micelles for DTX often lack in vivo stability, hindering their therapeutic potential.
- The Taxotere® formulation contains a toxic co-solvent causing adverse reactions.
Purpose of the Study:
- To develop a stable, water-soluble nano-carrier for docetaxel (DTX).
- To enhance drug-carrier compatibility using an ester prodrug of DTX, oligo(lactic acid)8-docetaxel (o(LA)8-DTX).
- To evaluate the efficacy and toxicity of the novel formulation in a preclinical prostate cancer model.
Main Methods:
- Synthesis of o(LA)8-DTX prodrug for improved compatibility with poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) micelles.
- Loading of o(LA)8-DTX into PEG-b-PLA micelles to achieve high drug concentration and controlled release.
- In vitro assessment of prodrug conversion to DTX and in vivo evaluation of micelle efficacy and toxicity in a mouse model of prostate cancer.
Main Results:
- High drug loading capacity (50% w/w prodrug) and solubilization of 20 mg/mL o(LA)8-DTX (~12 mg/mL DTX-equivalent) were achieved.
- The micelle core provided stability, preventing premature degradation, while released o(LA)8-DTX converted to DTX via intramolecular backbiting or esterase activity.
- o(LA)8-DTX micelles showed comparable efficacy to Taxotere® but with significantly reduced toxicity in a preclinical prostate cancer model.
Conclusions:
- The o(LA)8-DTX prodrug enhances compatibility with PEG-b-PLA micelles, enabling stable, high-load nano-formulations.
- This novel nano-formulation effectively delivers DTX, showing promise as a safer alternative to current treatments.
- The developed o(LA)8-DTX micelles represent a significant advancement in docetaxel delivery for prostate cancer therapy.
